Rxivist logo

Mutant p53 Drives Clonal Hematopoiesis through Modulating Epigenetic Pathway

By Sisi Chen, Qiang Wang, Hao Yu, Maegan L Capitano, Sasidhar Vemula, Sarah C Nabinger, Rui Gao, Chonghua Yao, Michihiro Kobayashi, Zhuangzhuang Geng, Aidan Fahey, Danielle Henley, Stephen Z Liu, Eric R Wolf, Baskar Ramdas, Zhigang Cai, Hongyu Gao, Na Luo, Yang Sun, Terrence N Wong, Daniel C Link, Yunlong Liu, H. Scott Boswell, Lindsey D Mayo, Gang Huang, Reuben Kapur, Mervin C Yoder, Hal E Broxmeyer, Zhonghua Gao, Yan Liu

Posted 24 Apr 2019
bioRxiv DOI: 10.1101/617779 (published DOI: 10.1038/s41467-019-13542-2)

Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and is associated with increased risks of hematological malignancies. While TP53 mutations have been identified in CHIP, the molecular mechanisms by which mutant p53 promotes hematopoietic stem and progenitor cell (HSPC) expansion are largely unknown. We discovered that mutant p53 confers a competitive advantage to HSPCs following transplantation and promotes HSPC expansion after radiation-induced stress. Mechanistically, mutant p53 interacts with EZH2 and enhances its association with the chromatin, thereby increasing the levels of H3K27me3 in genes regulating HSPC self-renewal and differentiation. Further, genetic and pharmacological inhibition of EZH2 decrease the repopulating potential of p53 mutant HSPCs. Thus, we have uncovered an epigenetic mechanism by which mutant p53 drives clonal hematopoiesis. Our work will likely establish epigenetic regulator EZH2 as a novel therapeutic target for preventing CHIP progression and treating hematological malignancies with TP53 mutations.

Download data

  • Downloaded 805 times
  • Download rankings, all-time:
    • Site-wide: 40,842
    • In cancer biology: 1,113
  • Year to date:
    • Site-wide: 143,781
  • Since beginning of last month:
    • Site-wide: 98,566

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide

PanLingua

News